{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:17:47Z","timestamp":1790104667051,"version":"4.0.1"},"reference-count":117,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Coleg Cymraeg Cenedlaethol"},{"name":"Janssen"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Diseases of the central nervous system, which once occupied a large component of the pharmaceutical industry research and development portfolio, have for many years played a smaller part in major pharma pipelines\u2014primarily due to the well cited challenges in target validation, valid translational models, and clinical trial design. Unfortunately, this decline in research and development interest has occurred in tandem with an increase in the medical need\u2014in part driven by the success in treating other chronic diseases, which then results in a greater overall longevity along with a higher prevalence of diseases associated with ageing. The lead modality for drug agents targeting the brain remains the traditionally small molecule, despite potential in gene-based therapies and antibodies, particularly in the hugely anticipated anti-amyloid field, clearly driven by the additional challenge of effective distribution to the relevant brain compartments. However, in recognition of the growing disease burden, advanced therapies are being developed in tandem with improved delivery options. Hence, methodologies which were initially restricted to systemic indications are now being actively explored for a range of CNS diseases\u2014an important class of which include the protein degradation technologies.<\/jats:p>","DOI":"10.3390\/biom13081164","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:45:02Z","timestamp":1690332302000},"page":"1164","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Central Nervous System Targeted Protein Degraders"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3020-0228","authenticated-orcid":false,"given":"Bedwyr ab Ion","family":"Thomas","sequence":"first","affiliation":[{"name":"Medicines Discovery Institute, Cardiff University, Cardiff CF10 3AT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Lois","family":"Lewis","sequence":"additional","affiliation":[{"name":"Medicines Discovery Institute, Cardiff University, Cardiff CF10 3AT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Heulyn","family":"Jones","sequence":"additional","affiliation":[{"name":"Medicines Discovery Institute, Cardiff University, Cardiff CF10 3AT, UK"},{"name":"Chemistry Department, Cardiff University, Cardiff CF10 3AT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8745-8377","authenticated-orcid":false,"given":"Simon E.","family":"Ward","sequence":"additional","affiliation":[{"name":"Medicines Discovery Institute, Cardiff University, Cardiff CF10 3AT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuropharm.2016.03.021","article-title":"The Need for New Approaches in CNS Drug Discovery: Why Drugs Have Failed, and What Can Be Done to Improve Outcomes","volume":"120","author":"Gribkoff","year":"2017","journal-title":"Neuropharmacology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41593-020-00778-1","article-title":"Gene-Based Therapies for Neurodegenerative Diseases","volume":"24","author":"Sun","year":"2021","journal-title":"Nat. Neurosci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/brain\/awad005","article-title":"Anti-Amyloid Antibody Therapies in Alzheimer\u2019s Disease","volume":"146","author":"Perneczky","year":"2023","journal-title":"Brain"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC Targeted Protein Degraders: The Past Is Prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/acs.jmedchem.7b01272","article-title":"Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?","volume":"61","author":"Churcher","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.chembiol.2017.05.024","article-title":"Targeted Protein Degradation: From Chemical Biology to Drug Discovery","volume":"24","author":"Cromm","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cbpa.2017.05.016","article-title":"Targeted Protein Knockdown Using Small Molecule Degraders","volume":"39","author":"Raina","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced Protein Degradation: An Emerging Drug Discovery Paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","article-title":"Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery","volume":"7","author":"Wager","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Tashima, T. (2023). Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier. Antibodies, 12.","DOI":"10.3390\/antib12030043"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acsmedchemlett.9b00083","article-title":"Treatment of Alzheimer\u2019s by PROTAC-Tau Protein Degradation","volume":"10","author":"Kargbo","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"16930","DOI":"10.1021\/jacs.2c05499","article-title":"Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Oral Bioavailable and Blood Brain Barrier Penetrant PROTAC Degrader of Leucine Rich Repeat Kinase 2","volume":"144","author":"Liu","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1021\/js9804011","article-title":"Rapid Calculation of Polar Molecular Surface Area and Its Application to the Prediction of Transport Phenomena. 1. Prediction of Intestinal Absorption","volume":"88","author":"Clark","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1021\/acs.jmedchem.1c00482","article-title":"Unraveling the Role of Linker Design in Proteolysis Targeting Chimeras","volume":"64","author":"Burkart","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"12639","DOI":"10.1021\/acs.jmedchem.2c00201","article-title":"Designing Soluble PROTACs: Strategies and Preliminary Guidelines","volume":"65","author":"Vallaro","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1042\/BJ20141450","article-title":"Targeting Cullin\u2013RING E3 Ubiquitin Ligases for Drug Discovery: Structure, Assembly and Small-Molecule Modulation","volume":"467","author":"Bulatov","year":"2015","journal-title":"Biochem. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1042\/BCJ20160762","article-title":"Chemical Approaches to Targeted Protein Degradation through Modulation of the Ubiquitin\u2013Proteasome Pathway","volume":"474","author":"Collins","year":"2017","journal-title":"Biochem. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1039\/C8CC09541H","article-title":"PROTAC-Mediated Crosstalk between E3 Ligases","volume":"55","author":"Steinebach","year":"2019","journal-title":"Chem. Commun."},{"key":"ref_20","unstructured":"Maneiro, M., de Vita, E., Conole, D., Kounde, C.S., Zhang, Q., and Tate, E.W. (2021). Progress in Medicinal Chemistry, Elsevier."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3389\/fphys.2020.01022","article-title":"E3 Ubiquitin Ligases in Neurological Diseases: Focus on Gigaxonin and Autophagy","volume":"11","author":"Bomont","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.chembiol.2021.04.002","article-title":"An E3 Ligase Guide to the Galaxy of Small-Molecule-Induced Protein Degradation","volume":"28","author":"Haakonsen","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/17460441.2021.1915979","article-title":"Is PROTAC Technology Really a Game Changer for Central Nervous System Drug Discovery?","volume":"16","author":"Farrell","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted Protein Degradation: Expanding the Toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1093\/bioinformatics\/bty1067","article-title":"UbiHub: A Data Hub for the Explorers of Ubiquitination Pathways","volume":"35","author":"Liu","year":"2019","journal-title":"Bioinformatics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cbpa.2019.02.022","article-title":"Targeted Protein Degradation: Elements of PROTAC Design","volume":"50","author":"Paiva","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1039\/C9MD00272C","article-title":"Developing Degraders: Principles and Perspectives on Design and Chemical Space","volume":"10","author":"Maple","year":"2019","journal-title":"Medchemcomm"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","article-title":"Plasticity in Binding Confers Selectivity in Ligand-Induced Protein Degradation","volume":"14","author":"Nowak","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric Molecules That Target Proteins to the Skp1-Cullin-F Box Complex for Ubiquitination and Degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"18082","DOI":"10.1021\/acs.jmedchem.1c01496","article-title":"Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity","volume":"64","author":"Klein","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1021\/acsmedchemlett.0c00265","article-title":"Understanding and Improving the Membrane Permeability of VH032-Based PROTACs","volume":"11","author":"Klein","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11066","DOI":"10.1021\/acs.jmedchem.2c00384","article-title":"Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13","volume":"65","author":"Yang","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1021\/acsmedchemlett.2c00124","article-title":"Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation","volume":"13","author":"Hendrick","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_34","unstructured":"(2023, February 09). Trial of ARV-110 in Patients with Metastatic Castration Resistant Prostate Cancer\u2014Full Text View\u2014ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03888612."},{"key":"ref_35","unstructured":"(2023, February 09). A Phase 1\/2 Trial of ARV-471 Alone and in Combination with Palbociclib (IBRANCE\u00ae) in Patients With ER+\/HER2- Locally Advanced or Metastatic Breast Cancer\u2014Full Text View\u2014ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04072952."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: Great Opportunities for Academia and Industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct. Target Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.chembiol.2016.02.016","article-title":"Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation","volume":"23","author":"Chu","year":"2016","journal-title":"Cell Chem. Biol."},{"key":"ref_38","unstructured":"Jansson, B. (2004). Models for the Transfer of Drugs from the Nasal Cavity to the Central Nervous System, Uppsala University."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejmech.2018.01.063","article-title":"Discovery of a Keap1-Dependent Peptide PROTAC to Knockdown Tau by Ubiquitination-Proteasome Degradation Pathway","volume":"146","author":"Lu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3233\/JAD-122059","article-title":"Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807","volume":"34","author":"Chien","year":"2013","journal-title":"J. Alzheimer Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jalz.2012.11.008","article-title":"[18F]T807, a Novel Tau Positron Emission Tomography Imaging Agent for Alzheimer\u2019s Disease","volume":"9","author":"Xia","year":"2013","journal-title":"Alzheimer Dement."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e45457","DOI":"10.7554\/eLife.45457","article-title":"Targeted Degradation of Aberrant Tau in Frontotemporal Dementia Patient-Derived Neuronal Cell Models","volume":"8","author":"Silva","year":"2019","journal-title":"Elife"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fncel.2022.801179","article-title":"Discovery and Optimization of Tau Targeted Protein Degraders Enabled by Patient Induced Pluripotent Stem Cells-Derived Neuronal Models of Tauopathy","volume":"16","author":"Silva","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.7150\/thno.55680","article-title":"A Novel Small-Molecule PROTAC Selectively Promotes Tau Clearance to Improve Cognitive Functions in Alzheimer-like Models","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"ref_45","unstructured":"Ferguson, F.M., Gray, N.S., Haggarty, S.J., and Telo Baptista Lima Da Silva, M.C. (2023). Targeted Degraders of Aberrant Tau Based on the PET Tracer PBB3. (US20230133538A1), US Patent."},{"key":"ref_46","unstructured":"Gray, N.S., Haggarty, S.J., Cai, Q., Telo Baptista Lima Da Silva, M.C., Zhang, T., and Ferguson, F.M. (2019). Compounds for Tau Protein Degradation. (WO2019014429A1), European Patent."},{"key":"ref_47","unstructured":"(2022, April 21). Arvinas Arvinas to Present Preclinical Tau-Directed PROTAC\u00ae Protein Degrader Data at Alzheimer\u2019s Association International Conference\u2014Arvinas. Available online: www.arvinas.com."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"11530","DOI":"10.1002\/anie.201706529","article-title":"Discovery of Small Molecules That Induce the Degradation of Huntingtin","volume":"56","author":"Tomoshige","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/anie.202004746","article-title":"PROTACs and Other Chemical Protein Degradation Technologies for the Treatment of Neurodegenerative Disorders","volume":"60","author":"Tomoshige","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bmcl.2018.01.012","article-title":"Degradation of Huntingtin Mediated by a Hybrid Molecule Composed of IAP Antagonist Linked to Phenyldiazenyl Benzothiazole Derivative","volume":"28","author":"Tomoshige","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ebiom.2018.09.005","article-title":"Small-Molecule PROTACs: An Emerging and Promising Approach for the Development of Targeted Therapy Drugs","volume":"36","author":"An","year":"2018","journal-title":"EBioMedicine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/anie.201507978","article-title":"Small-Molecule PROTACS: New Approaches to Protein Degradation","volume":"55","author":"Toure","year":"2016","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1326-9-47","article-title":"The Role of the LRRK2 Gene in Parkinsonism","volume":"9","author":"Li","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/hmg\/ddl471","article-title":"Parkinson\u2019s Disease-Associated Mutations in LRRK2 Link Enhanced GTP-Binding and Kinase Activities to Neuronal Toxicity","volume":"16","author":"West","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cmdc.202000872","article-title":"The Tale of Proteolysis Targeting Chimeras (PROTACs) for Leucine-Rich Repeat Kinase 2 (LRRK2)","volume":"16","author":"Konstantinidou","year":"2021","journal-title":"ChemMedChem"},{"key":"ref_56","unstructured":"Araujo, E., Berlin, M., Sparks, S.M., Wang, J., and Zhang, W. (2022). Selective Modulators of Mutant LRRK2 Proteolysis and Associated Methods of Use. (US20220064168A1), US Patent."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"\u03b1-Synuclein in Lewy Bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.chembiol.2020.03.010","article-title":"Specific Knockdown of \u03b1-Synuclein by Peptide-Directed Proteasome Degradation Rescued Its Associated Neurotoxicity","volume":"27","author":"Qu","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1021\/acsmedchemlett.0c00192","article-title":"PROTAC Compounds Targeting \u03b1-Synuclein Protein for Treating Neurogenerative Disorders: Alzheimer\u2019s and Parkinson\u2019s Diseases","volume":"11","author":"Kargbo","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_60","unstructured":"Crew, A.P., Dong, H., Berlin, M., and Sparks, S.M. (2020). Proteolysis Targeting Chimeric (PROTAC) Compound with E3 Ubiquitin Ligase Binding Activity and Targeting Alpha-Synuclein Protein for Treating Neurodegenerative Diseases. (WO2020041331A1), European Patent."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s12276-020-00513-7","article-title":"The Role of TDP-43 Propagation in Neurodegenerative Diseases: Integrating Insights from Clinical and Experimental Studies","volume":"52","author":"Jo","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12929-023-00921-7","article-title":"Degradation of Neurodegenerative Disease-Associated TDP-43 Aggregates and Oligomers via a Proteolysis-Targeting Chimera","volume":"30","author":"Tseng","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1039\/D2CS00200K","article-title":"Target and Tissue Selectivity of PROTAC Degraders","volume":"51","author":"Guenette","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"8701","DOI":"10.1523\/JNEUROSCI.2133-14.2015","article-title":"Loss of the Neuron-Specific F-Box Protein FBXO41 Models an Ataxia-Like Phenotype in Mice with Neuronal Migration Defects and Degeneration in the Cerebellum","volume":"35","author":"Mukherjee","year":"2015","journal-title":"J. Neurosci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"12016","DOI":"10.1073\/pnas.0802261105","article-title":"Deficiency in Ubiquitin Ligase TRIM2 Causes Accumulation of Neurofilament Light Chain and Neurodegeneration","volume":"105","author":"Balastik","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.devcel.2015.11.022","article-title":"The E3 Ubiquitin Ligase TRIM9 Is a Filopodia Off Switch Required for Netrin-Dependent Axon Guidance","volume":"35","author":"Menon","year":"2015","journal-title":"Dev. Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"114290","DOI":"10.1016\/j.ejmech.2022.114290","article-title":"The State of the Art of PROTAC Technologies for Drug Discovery","volume":"235","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrd3980","article-title":"Antibody\u2013Drug Conjugates","volume":"12","author":"Zolot","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/acschembio.0c00285","article-title":"Antibody\u2013PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4","volume":"15","author":"Maneiro","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"126907","DOI":"10.1016\/j.bmcl.2019.126907","article-title":"Antibody-Mediated Delivery of Chimeric Protein Degraders Which Target Estrogen Receptor Alpha (ER\u03b1)","volume":"30","author":"Dragovich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1016\/j.apsb.2022.02.022","article-title":"Non-Small Molecule PROTACs (NSM-PROTACs): Protein Degradation Kaleidoscope","volume":"12","author":"Ma","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/cmdc.201900497","article-title":"Antibody Conjugation of a Chimeric BET Degrader Enables In Vivo Activity","volume":"15","author":"Pillow","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jacs.0c10008","article-title":"Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1","volume":"143","author":"Cotton","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1038\/ncomms3787","article-title":"Structural and Molecular Basis of ZNRF3\/RNF43 Transmembrane Ubiquitin Ligase Inhibition by the Wnt Agonist R-Spondin","volume":"4","author":"Zebisch","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_75","first-page":"311","article-title":"Engineering Antibody and Protein Therapeutics to Cross the Blood\u2013Brain Barrier","volume":"5","author":"Zhao","year":"2022","journal-title":"Antib. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tips.2020.04.005","article-title":"Emerging New Concepts of Degrader Technologies","volume":"41","author":"Ding","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"100647","DOI":"10.1016\/j.jbc.2021.100647","article-title":"Major Advances in Targeted Protein Degradation: PROTACs, LYTACs, and MADTACs","volume":"296","author":"Alabi","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1535-7163.MCT-18-1129","article-title":"Acquired Resistance to BET-ProTACS (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of Proteins by PROTACs and Other Strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Uhl\u00e9n, M., Fagerberg, L., Hallstr\u00f6m, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, \u00c5., Kampf, C., Sj\u00f6stedt, E., and Asplund, A. (2015). Tissue-Based Map of the Human Proteome. Science, 347.","DOI":"10.1126\/science.1260419"},{"key":"ref_81","first-page":"1117","article-title":"Plasticity of Tumor Cell Invasion: Governance by Growth Factors and Cytokines","volume":"37","author":"Odenthal","year":"2016","journal-title":"Carcinogenesis"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1002\/anie.201503720","article-title":"Hot Paper Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging","volume":"54","author":"Gustafson","year":"2015","journal-title":"Angew. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Hyun, S., Shin, D., Park, S.J., Choi, J.W., and Kim, H. (2021). Chemical-Mediated Targeted Protein Degradation in Neurodegenerative Diseases. Life, 11.","DOI":"10.3390\/life11070607"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"101616","DOI":"10.1016\/j.arr.2022.101616","article-title":"Targeted Protein Degraders March towards the Clinic for Neurodegenerative Diseases","volume":"78","author":"Kumar","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"ref_85","first-page":"402","article-title":"Conversion of a PROTAC Mutant Huntingtin Degrader into Small-Molecule Hydrophobic Tags Focusing on Drug-like Properties","volume":"2022","author":"Hirai","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"40362","DOI":"10.1039\/C7RA05347A","article-title":"Hydrophobic Tagging-Mediated Degradation of Alzheimer\u2019s Disease Related Tau","volume":"7","author":"Gao","year":"2017","journal-title":"RSC Adv."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.bioorg.2018.11.042","article-title":"TDP-43 Specific Reduction Induced by Di-Hydrophobic Tags Conjugated Peptides","volume":"84","author":"Gao","year":"2019","journal-title":"Bioorg. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1021\/acs.jmedchem.0c01689","article-title":"Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery","volume":"64","author":"Pei","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_89","unstructured":"Cooper, G.M. (2000). The Cell: A Molecular Approach, Sinauer Associates."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40035-015-0041-1","article-title":"The endosomal-lysosomal system: From acidification and cargo sorting to neurodegeneration","volume":"4","author":"Hu","year":"2015","journal-title":"Transl. Neurodegener."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jmb.2016.02.004","article-title":"Mechanisms of Selective Autophagy","volume":"428","author":"Zaffagnini","year":"2016","journal-title":"J. Mol. Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"24131","DOI":"10.1074\/jbc.M702824200","article-title":"P62\/SQSTM1 Binds Directly to Atg8\/LC3 to Facilitate Degradation of Ubiquitinated Protein Aggregates by Autophagy","volume":"282","author":"Pankiv","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/cr.2013.168","article-title":"The Machinery of Macroautophagy 24 The Machinery of Macroautophagy","volume":"24","author":"Feng","year":"2014","journal-title":"Cell Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/path.2697","article-title":"Autophagy: Cellular and Molecular Mechanisms","volume":"221","author":"Glick","year":"2010","journal-title":"J. Pathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2007.12.018","article-title":"Autophagy in the Pathogenesis of Disease","volume":"132","author":"Levine","year":"2008","journal-title":"Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev.nutr.27.061406.093749","article-title":"Protein Turnover Via Autophagy: Implications for Metabolism","volume":"27","author":"Mizushima","year":"2007","journal-title":"Annu. Rev. Nutr."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-Targeting Chimaeras for Degradation of Extracellular Proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/acscentsci.1c00146","article-title":"Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins","volume":"7","author":"Zhou","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Zhu, W., Gao, M., Chen, B., Tan, T., Cao, H., and Liu, L. (2019). The Synthesis of Mannose-6-Phosphate Using Polyphosphate-Dependent Mannose Kinase. Catalysts, 9.","DOI":"10.3390\/catal9030250"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/biol.2001.0308","article-title":"Antigenicity and Immunogenicity of Synthetic Peptides","volume":"29","year":"2001","journal-title":"Biologicals"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"8337","DOI":"10.7150\/thno.62686","article-title":"Emerging Protein Degradation Strategies: Expanding the Scope to Extracellular and Membrane Proteins","volume":"11","author":"Lin","year":"2021","journal-title":"Theranostics"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: Cargo-Specific Degraders Using Selective Autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.molcel.2009.04.026","article-title":"A Role for Ubiquitin in Selective Autophagy","volume":"34","author":"Kirkin","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/15548627.2020.1718362","article-title":"Targeting Selective Autophagy by AUTAC Degraders","volume":"16","author":"Takahashi","year":"2020","journal-title":"Autophagy"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41467-022-28520-4","article-title":"The AUTOTAC Chemical Biology Platform for Targeted Protein Degradation via the Autophagy-Lysosome System","volume":"13","author":"Lim","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13045-021-01146-7","article-title":"Protein Degradation Technology: A Strategic Paradigm Shift in Drug Discovery","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1021\/acs.jmedchem.1c00895","article-title":"Molecular Glues for Targeted Protein Degradation: From Serendipity to Rational Discovery","volume":"64","author":"Dong","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1021\/acs.jmedchem.9b00846","article-title":"Simple Structural Modifications Converting a Bona Fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders","volume":"62","author":"Yang","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1021\/acschembio.7b00969","article-title":"Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders","volume":"13","author":"Ishoey","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/15548627.2019.1688556","article-title":"ATTEC: A Potential New Approach to Target Proteinopathies","volume":"16","author":"Li","year":"2020","journal-title":"Autophagy"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-Selective Lowering of Mutant HTT Protein by HTT\u2013LC3 Linker Compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nprot.2013.055","article-title":"Imaging of Neutral Lipids by Oil Red O for Analyzing the Metabolic Status in Health and Disease","volume":"8","author":"Mehlem","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41422-021-00532-7","article-title":"Degradation of Lipid Droplets by Chimeric Autophagy-Tethering Compounds","volume":"31","author":"Fu","year":"2021","journal-title":"Cell Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1080\/15548627.2021.1967616","article-title":"Targeting Lipid Droplets for Autophagic Degradation by ATTEC","volume":"17","author":"Fu","year":"2021","journal-title":"Autophagy"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41580-018-0001-6","article-title":"The Coming of Age of Chaperone-Mediated Autophagy","volume":"19","author":"Kaushik","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nn.3637","article-title":"Rapid and Reversible Knockdown of Endogenous Proteins by Peptide-Directed Lysosomal Degradation","volume":"17","author":"Fan","year":"2014","journal-title":"Nat. Neurosci."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Shaltiel-Karyo, R., Frenkel-Pinter, M., Egoz-Matia, N., Frydman-Marom, A., Shalev, D.E., Segal, D., and Gazit, E. (2010). Inhibiting \u03b1-Synuclein Oligomerization by Stable Cell-Penetrating \u03b2-Synuclein Fragments Recovers Phenotype of Parkinson\u2019s Disease Model Flies. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0013863"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/8\/1164\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:18:42Z","timestamp":1760127522000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/8\/1164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":117,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["biom13081164"],"URL":"https:\/\/doi.org\/10.3390\/biom13081164","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]}}}